Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on invested capital (ROIC) is N/A as of the fiscal period ended Thursday, April 30, 2026.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q1 FY2026 (2026-04-30): -103.64%.
RETURN ON INVESTED CAPITAL (ROIC)
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-151.25%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-174.80%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-119.96%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
GRI Bio, Inc.
Market Cap
$4.11M
Return on Invested Capital (ROIC)
N/A
TTM Avg
-151.25%
3Y Avg
-174.80%
5Y Avg
-119.96%
Market Cap
$4.01M
Return on Invested Capital (ROIC)
-288.14%
TTM Avg
-190.86%
3Y Avg
-162.44%
5Y Avg
-129.35%
Market Cap
$4.65M
Return on Invested Capital (ROIC)
-116.89%
TTM Avg
-117.72%
3Y Avg
-83.78%
5Y Avg
-61.46%
Market Cap
$4.34M
Return on Invested Capital (ROIC)
-346.94%
TTM Avg
-467.60%
3Y Avg
-296.93%
5Y Avg
-277.74%
Market Cap
$4.43M
Return on Invested Capital (ROIC)
-221.32%
TTM Avg
-119.11%
3Y Avg
-77.97%
5Y Avg
-64.48%
Market Cap
$4.55M
Return on Invested Capital (ROIC)
-246.61%
TTM Avg
-463.24%
3Y Avg
-303.42%
5Y Avg
-359.05%
Market Cap
$3.59M
Return on Invested Capital (ROIC)
-33.50%
TTM Avg
-18.16%
3Y Avg
-45.78%
5Y Avg
-36.63%
Market Cap
$3.70M
Return on Invested Capital (ROIC)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.54M
Return on Invested Capital (ROIC)
-45.77%
TTM Avg
-25.13%
3Y Avg
-754.36%
5Y Avg
-475.60%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GRI Bio, Inc. (GRI) | $4.11M | N/A | -151.25% | -174.80% | -119.96% |
| Aptevo Therapeutics Inc. (APVO)vs › | $4.01M | -288.14% | -190.86% | -162.44% | -129.35% |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.65M | -116.89% | -117.72% | -83.78% | -61.46% |
| Ernexa Therapeutics Inc. (ERNA)vs › | $4.34M | -346.94% | -467.60% | -296.93% | -277.74% |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.43M | -221.32% | -119.11% | -77.97% | -64.48% |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.55M | -246.61% | -463.24% | -303.42% | -359.05% |
| Moolec Science S.A. (MLEC)vs › | $3.59M | -33.50% | -18.16% | -45.78% | -36.63% |
| Eocene Ltd. (EOCN)vs › | $3.70M | N/A | N/A | N/A | N/A |
| Mustang Bio, Inc. (MBIO)vs › | $3.54M | -45.77% | -25.13% | -754.36% | -475.60% |
| Evogene Ltd. (EVGN)vs › | $3.41M | -130.12% | -72.08% | -61.96% | -55.38% |
ROIC
N/A
ROE
N/A
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-04-30 | -103.64% |
| 2026-01-31 | -198.85% |
| 2024-10-31 | -221.90% |
| 2022-06-30 | -50.72% |
| 2022-03-31 | -117.15% |
| 2021-12-31 | -106.80% |
| 2021-09-30 | -86.38% |
| 2021-06-30 | -74.23% |
| 2021-03-31 | -50.78% |
| 2020-09-30 | -1317.06% |
| 2020-06-30 | -299.35% |
| 2019-12-31 | -88.82% |